1-5 of 5
Craig Underhill
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers

Available to Purchase
Oliver Klein, Damien Kee, Ben Markman, Michael Michael, Craig Underhill, Matteo S. Carlino, Louise Jackett, Caroline Lum, Clare Scott, Adnan Nagrial, Andreas Behren, Jane Y. So, Jodie Palmer, Jonathan Cebon
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4454–4459.
https://doi.org/10.1158/1078-0432.CCR-20-0621
Published: 01 September 2020
View articletitled, Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
Open the PDF for Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers in another window
Includes: Supplementary data
Journal Articles

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study

Free
C. Kent Osborne, Patrick Neven, Luc Y. Dirix, John R. Mackey, Jean Robert, Craig Underhill, Rachel Schiff, Carolina Gutierrez, Ilenia Migliaccio, Valsamo K. Anagnostou, David L. Rimm, Patrick Magill, Mark Sellers
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (5): 1147–1159.
https://doi.org/10.1158/1078-0432.CCR-10-1869
Published: 01 March 2011
View articletitled, Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study
Open the PDF for Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study in another window
Journal Articles

Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma

Free
Maher K. Gandhi, Eleanore Lambley, Jacqueline Burrows, Ujjwal Dua, Suzanne Elliott, Peter J. Shaw, H. Miles Prince, Max Wolf, Kerrie Clarke, Craig Underhill, Tony Mills, Peter Mollee, Devinder Gill, Paula Marlton, John F. Seymour, Rajiv Khanna
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (2): 460–464.
https://doi.org/10.1158/1078-0432.CCR-05-2008
Published: 20 January 2006
View articletitled, Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma
Open the PDF for Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma in another window
Journal Articles

A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma

Free
H Miles Prince, Linda Mileshkin, Andrew Roberts, Vinod Ganju, Craig Underhill, John Catalano, Richard Bell, John F. Seymour, David Westerman, Paul J. Simmons, Kate Lillie, Alvin D. Milner, Juliana Di Iulio, Jerome B. Zeldis, Robert Ramsay
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (15): 5504–5514.
https://doi.org/10.1158/1078-0432.CCR-05-0213
Published: 01 August 2005
View articletitled, A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma
Open the PDF for A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma in another window
Journal Articles

A Phase I Study of Recombinant Human Leukemia Inhibitory Factor in Patients with Advanced Cancer

Free
Dishan H. Gunawardana, Russell L. Basser, Ian D. Davis, Jonathan Cebon, Paul Mitchell, Craig Underhill, Trevor J. Kilpatrick, Katrina Reardon, Michael D. Green, Peter Bardy, Pene Amor, David Crump, Siobhan Ng, Roger L. Nation, C. Glenn Begley
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (6): 2056–2065.
Published: 01 June 2003
View articletitled, A Phase I Study of Recombinant Human Leukemia Inhibitory Factor in Patients with Advanced Cancer
Open the PDF for A Phase I Study of Recombinant Human Leukemia Inhibitory Factor in Patients with Advanced Cancer in another window